Veludacigib - Bayer
Alternative Names: BAY-2965501Latest Information Update: 22 Apr 2026
At a glance
- Originator Bayer
- Class Amides; Amines; Antineoplastics; Fluorobenzenes; Ketones; Methyl ethers; Phenyl ethers; Small molecules; Thiazepines
- Mechanism of Action DGKZ protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Apr 2026 Chemical structure information added.
- 28 Dec 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, In adults) in USA (PO, Tablet)
- 12 Nov 2025 Bayer terminates phase I trial in Solid tumours (Late-stage disease, Monotherapy, Combination therapy) in Belgium, USA, China, Japan, South Korea, Spain, United Kingdom (PO) (NCT05614102)